此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

优化阿片类药物使用障碍药物治疗 (RDD) 的保留、持续时间和停药策略

2026年11月9日 更新者:NYU Langone Health

NIDA-CTN-0100:优化阿片类药物使用障碍药物治疗 (RDD) 的保留、持续时间和停药策略

This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.

研究概览

详细说明

The main objectives of this study are:

  1. To test strategies to improve retention in treatment on medications for opioid use disorder (MOUD), among patients initiating treatment for OUD.
  2. To test strategies to improve outcomes among patients who have achieved stable remission on MOUD and want to discontinue MOUD.
  3. To develop models to predict who is able to discontinue MOUD without relapse, based on patient characteristics, including duration of MOUD prior to discontinuation.

The study will have a multicenter, randomized, pragmatic non-blinded design. The study has two phases, a Retention Phase and a Discontinuation Phase.

研究类型

介入性

注册 (实际的)

1516

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Arkansas
      • Little Rock、Arkansas、美国、72205
        • University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST)
    • California
      • Tarzana、California、美国、91356
        • Tarzana Treatment Centers, Inc.
    • Connecticut
      • Bridgeport、Connecticut、美国、06610
        • Liberation Programs, Inc.
    • Florida
      • Clearwater、Florida、美国、33760
        • Operation PAR
      • Jacksonville、Florida、美国、32204
        • Gateway Community Services
      • Orlando、Florida、美国、32806
        • Aspire Health Partners
    • Maryland
      • Baltimore、Maryland、美国、21229
        • Mountain Manor / Maryland Treatment Centers
    • Massachusetts
      • Belmont、Massachusetts、美国、02478
        • McLean Hospital
      • Fall River、Massachusetts、美国、02720
        • Stanley Street Treatment and Resources, Inc.
      • Newton、Massachusetts、美国、02458
        • Square Medical Group, LLC
    • Missouri
      • Cape Girardeau、Missouri、美国、63703
        • Gibson Center for Behavioral Change
    • New Hampshire
      • Lebanon、New Hampshire、美国、03766
        • Dartmouth Hitchcock - ATP
    • New Mexico
      • Albuquerque、New Mexico、美国、87106
        • University of New Mexico Addiction and Substance Abuse Program
    • New York
      • New York、New York、美国、10016
        • Bellevue Hospital Center
    • Oregon
      • Roseburg、Oregon、美国、97470
        • Adapt Integrated Health Care
      • Winston、Oregon、美国、97496
        • Adapt Integrated Health Care
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15213
        • Center for Psychiatric and Chemical Dependency Services (CPCDS)
      • Pittsburgh、Pennsylvania、美国、15219
        • Internal Medicine Recovery Engagement Program (IM-REP)
    • South Carolina
      • Conway、South Carolina、美国、29526
        • Shoreline Behavioral Health Services
    • Utah
      • Salt Lake City、Utah、美国、84108
        • Huntsman Mental Health Institute / University of Utah
    • West Virginia
      • Morgantown、West Virginia、美国、26505
        • Chestnut Ridge Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria for Retention Phase:

  1. 18 years of age or older;
  2. Meet DSM-5 criteria for current opioid use disorder (heroin, fentanyl or other synthetic opioids, and/or prescription opioids);
  3. Seeking treatment for opioid use disorder and choosing either buprenorphine (BUP) or extended-release injection naltrexone (XR-NTX);
  4. If choosing buprenorphine, willing to be randomized to SL-BUP-16mg, SL-BUP-32mg, or XR-BUP;
  5. Willing to be randomized to either MM (standard Medical Management plus counseling treatment as usual available at the site) or MMR (MM plus usual counseling and access to an app delivering CM + CBT);
  6. In good-enough general health (meaning good enough health to be in outpatient treatment) as determined by the study medical clinician on the basis of medical history, review of systems, and physical/mental status exam, to permit treatment with XR-NTX or BUP;
  7. Willing and able to provide written informed consent;
  8. Able to speak English sufficiently to understand the study procedures;
  9. If female of childbearing potential, willing to practice an effective method of birth control for the duration of participation in the study (participants who become pregnant during the study will continue to be followed; treatment may be modified consistent with pregnancy).

Exclusion Criteria for Retention Phase:

  1. Serious medical, psychiatric, or co-occurring substance use disorder or concomitant medication that, in the opinion of the study medical clinician, makes the patient not appropriate for outpatient treatment with buprenorphine or XR-NTX, but instead requires a higher or different level of care. Examples include:

    1. Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
    2. Severe, untreated or inadequately treated psychiatric condition (e.g., active psychosis, uncontrolled bipolar disorder) as assessed by history and/or clinical interview, requiring a different level of care (e.g., hospitalization);
    3. Current severe alcohol, benzodiazepine, or other depressant or sedative hypnotic use, requiring a different level of care (e.g., hospitalization);
  2. Suicidal or homicidal ideation or behavior requiring a different level of care (e.g., hospitalization);

  3. Known allergy or sensitivity to preferred medication or its components;

  4. Maintenance on methadone at the time of signing consent;

  5. For those preferring XR-NTX, presence of pain of sufficient severity as to require ongoing pain management with opioids;

  6. For those preferring XR-NTX, body habitus that, in the judgment of the study physician, precludes safe intramuscular injection of XR-NTX (e.g., BMI>40, excess fat tissue over the buttocks, emaciation);

  7. If female, currently pregnant or breastfeeding or planning on conception;

  8. Are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities;

  9. Have used the reSET-O or CHESS Connections mHealth apps in the 3 months prior to consent;

  10. Other major reasons that might prevent an individual from participating in the study (e.g., a planned move out of the area).

Inclusion Criteria for Discontinuation Phase:

  1. 18 years of age or older;
  2. Have been receiving buprenorphine for OUD for at least the past year or XR-NTX pharmacotherapy for OUD for at least the past 6 months prior to consent for the Discontinuation Phase;
  3. Express the desire to discontinue MOUD after a shared decision-making discussion with the treating provider;
  4. Meet stability criteria, i.e., have abstained from opioids (other than buprenorphine), cocaine, methamphetamine, and non-prescribed benzodiazepines for the past ≥12 weeks, and do not meet DSM-5 criteria for current (≥12 weeks) alcohol use disorder (participants with cannabis use will be eligible);
  5. If currently taking buprenorphine, are willing to take either SL-BUP or XR-BUP if randomized to that condition;
  6. Willing to be randomized to either MM or to MMD;
  7. Able to provide written informed consent after discussion with their provider regarding the risks of discontinuation;
  8. Able to speak English sufficiently to understand the study procedures;
  9. If female of childbearing potential, willing to practice an effective method of birth control while in the study and taking study medication (participants who become pregnant during the study will continue to be followed; treatment may be modified consistent with pregnancy).

Exclusion Criteria for Discontinuation Phase:

  1. Serious medical or psychiatric disorder or concomitant medication that, in the opinion of the study medical clinician, would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study. Examples include:

    1. Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
    2. Severe, untreated, or inadequately treated psychiatric condition (e.g., active psychosis, uncontrolled bipolar disorder) as assessed by history and/or clinical interview, requiring a different level of care (e.g., hospitalization);
  2. Suicidal or homicidal ideation or behavior requiring a different level of care (e.g., hospitalization);

  3. For participants entering the study taking buprenorphine, presence of pain requiring or likely requiring ongoing pain management with buprenorphine or other opioids;

  4. If female, currently pregnant or breastfeeding or planning on conception;

  5. Use of opioids (other than buprenorphine), cocaine, methamphetamine, or non-prescribed benzodiazepines in the past 12 weeks;

  6. Meets current DSM-5 criteria for any current alcohol use disorder;

  7. Are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities;

  8. Have used the Connections mHealth app in the 3 months prior to consent (other than Connections in the Retention Phase);

  9. Other major reasons that might prevent an individual from participating in the study (e.g., a planned move out of the area.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:阶乘赋值
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Retention: SL-BUP standard dose + MM

Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

Daily dosing of sublingual buprenorphine-naloxone

其他名称:
  • 亚酮
  • 舌下含服丁丙诺啡

MM consists of standard Medical Management and the usual counseling at the treatment program.

实验性的:Retention: SL-BUP high dose + MM

High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

Daily dosing of sublingual buprenorphine-naloxone

其他名称:
  • 亚酮
  • 舌下含服丁丙诺啡

MM consists of standard Medical Management and the usual counseling at the treatment program.

实验性的:Retention: XR-BUP + MM

Extended-release injectable buprenorphine (XR-BUP) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Weekly/monthly dosing of extended-release injectable buprenorphine

其他名称:
  • CAM2038
  • 缓释丁丙诺啡
  • 布里沙迪
实验性的:Retention: XR-NTX + MM

Extended-release injectable naltrexone (XR-NTX) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Monthly dosing of extended-release injectable naltrexone

其他名称:
  • 维维特罗
  • 缓释纳曲酮
实验性的:Retention: SL-BUP standard dose + MMR

Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MMR, consisting of Medical Management and usual counseling, plus a technology-based behavioral component.

Daily dosing of sublingual buprenorphine-naloxone

其他名称:
  • 亚酮
  • 舌下含服丁丙诺啡

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

实验性的:Retention: SL-BUP high dose + MMR

High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Daily dosing of sublingual buprenorphine-naloxone

其他名称:
  • 亚酮
  • 舌下含服丁丙诺啡

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

实验性的:Retention: XR-BUP + MMR

Extended-release injectable buprenorphine (XR-BUP) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Weekly/monthly dosing of extended-release injectable buprenorphine

其他名称:
  • CAM2038
  • 缓释丁丙诺啡
  • 布里沙迪

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

实验性的:Retention: XR-NTX + MMR

Extended-release injectable naltrexone (XR-NTX) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Monthly dosing of extended-release injectable naltrexone

其他名称:
  • 维维特罗
  • 缓释纳曲酮

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

实验性的:Discontinuation: Discontinue SL-BUP with SL-BUP + MM

Start on SL-BUP, taper with SL-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

Daily dosing of sublingual buprenorphine-naloxone

其他名称:
  • 亚酮
  • 舌下含服丁丙诺啡

MM consists of standard Medical Management and the usual counseling at the treatment program.

实验性的:Discontinuation: Discontinue SL-BUP with XR-BUP + MM

Start on SL-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Weekly/monthly dosing of extended-release injectable buprenorphine

其他名称:
  • CAM2038
  • 缓释丁丙诺啡
  • 布里沙迪
实验性的:Discontinuation: Discontinue XR-BUP with XR-BUP + MM

Start on XR-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Weekly/monthly dosing of extended-release injectable buprenorphine

其他名称:
  • CAM2038
  • 缓释丁丙诺啡
  • 布里沙迪
实验性的:Discontinuation: Discontinue XR-NTX with XR-NTX + MM

Start on XR-NTX, taper with XR-NTX, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Monthly dosing of extended-release injectable naltrexone

其他名称:
  • 维维特罗
  • 缓释纳曲酮
实验性的:Discontinuation: Discontinue SL-BUP with SL-BUP + MMD

Start on SL-BUP, taper with SL-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Daily dosing of sublingual buprenorphine-naloxone

其他名称:
  • 亚酮
  • 舌下含服丁丙诺啡

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

实验性的:Discontinuation: Discontinue SL-BUP with XR-BUP + MMD

Start on SL-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Weekly/monthly dosing of extended-release injectable buprenorphine

其他名称:
  • CAM2038
  • 缓释丁丙诺啡
  • 布里沙迪

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

实验性的:Discontinuation: Discontinue XR-BUP with XR-BUP + MMD

Start on XR-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Weekly/monthly dosing of extended-release injectable buprenorphine

其他名称:
  • CAM2038
  • 缓释丁丙诺啡
  • 布里沙迪

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

实验性的:Discontinuation: Discontinue XR-NTX with XR-NTX + MMD

Start on XR-NTX, taper with XR-NTX, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Monthly dosing of extended-release injectable naltrexone

其他名称:
  • 维维特罗
  • 缓释纳曲酮

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Retention: Continuous retention in MOUD treatment through 26 weeks
大体时间:Retention: from randomization through week 26

Binary (yes/no). Continuously enrolled in maintenance treatment on one or more of the evidence-based MOUD modalities (e.g., SL-BUP, XR-BUP, XR-NTX, or methadone maintenance) with no more than a 28-day gap on MOUD over the 26-week period.

Retention: from randomization through week 26
Discontinuation: Completed Discontinuation without Relapse
大体时间:Discontinuation: from randomization through week 24 follow up

Binary (yes/no). Discontinuing MOUD during the taper period, no return to MOUD, and no relapse to opioid use, either during the taper (up to 48 weeks for those entering on BUP or 24 weeks for those entering on XR-NTX) or during the 24 weeks after MOUD is discontinued.

Discontinuation: from randomization through week 24 follow up

次要结果测量

结果测量
措施说明
大体时间
Retention KS1: Weekly opioid abstinence
大体时间:Retention: from randomization through week 26

Weekly opioid abstinence (measured by Timeline Followback, not contradicted by toxicology test). Repeated yes/no measure for each of weeks 1 through 26.

Retention: from randomization through week 26
Retention KS2: Treatment effectiveness
大体时间:Retention: at week 26

Retention treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 26.

Retention: at week 26
Retention KS3: Treatment by baseline severity
大体时间:Retention: at week 26

Treatment by baseline severity interaction where severity is indicated by the randomization stratum injection use (yes/no).

Retention: at week 26
Discontinuation KS1: Completed Discontinuation
大体时间:Discontinuation: from randomization through week 24 follow up

Completed Discontinuation without regard to relapse status

Discontinuation: from randomization through week 24 follow up
Discontinuation KS2: Relapse
大体时间:Discontinuation: from randomization through week 24 follow up

Relapse - separate binary outcome without regard to discontinuation status

Discontinuation: from randomization through week 24 follow up
Discontinuation KS3: Safety
大体时间:Discontinuation: from randomization through week 24 follow up

Safety outcomes (binary, any one or more occurrences): overdoses, all non-fatal plus fatal.

Discontinuation: from randomization through week 24 follow up
Discontinuation KS4: Treatment effectiveness
大体时间:Discontinuation: at end of taper (EoT) and week 24 follow up

Discontinuation treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 24. Measured at the end of taper (EOT): up to 24 weeks for tapers with XR-NTX and up to 48 weeks for tapers with BUP; and at the week 24 follow up (primary outcome timepoint).

Discontinuation: at end of taper (EoT) and week 24 follow up

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Edward V Nunes, MD、New York State Psychiatric Institute/Columbia University Irving Medical Center
  • 首席研究员:Roger Weiss, MD、Harvard Medical School/McLean Hospital
  • 首席研究员:John Rotrosen, MD、NYU Langone Health

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年6月8日

初级完成 (估计的)

2026年12月31日

研究完成 (估计的)

2027年1月31日

研究注册日期

首次提交

2020年6月29日

首先提交符合 QC 标准的

2020年7月6日

首次发布 (实际的)

2020年7月9日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • 19-01363
  • UG1DA015831 (美国 NIH 拨款/合同)
  • CTN-0100 (其他标识符:NIDA Clinical Trials Network)
  • UG1DA013035 (美国 NIH 拨款/合同)
  • 20-PRS-057 (其他标识符:Biomedical Research Alliance of New York (BRANY) sIRB)
  • 146193 (其他标识符:FDA/IND#)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

This study will comply with the NIH Data Sharing Policy and Implementation Guidance (https://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm) and (for HEAL-funded studies) the HEAL Public Access and Data Sharing Policy (https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/research/heal-public-access-data-sharing-policy).

Primary data for this study will be available to the public in the NIDA data repository. For more details on data sharing please visit https://datashare.nida.nih.gov/.

The primary outcome(s) publication will be included along with study underlying primary data in the data share repository, and it will also be deposited in PubMed Central http://www.pubmedcentral.nih.gov/ per NIH Policy (http://publicaccess.nih.gov/).

IPD 共享时间框架

Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

IPD 共享支持信息类型

  • 研究方案
  • 树液

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅